搜索
 > 【CD23】重组蛋白信息

CD23信息

英文名称:Immunoglobulin epsilon Fc receptor
中文名称:免疫球蛋白ε-Fc受体
靶点别称:Low affinity immunoglobulin epsilon Fc receptor soluble form,Lymphocyte IgE receptor,Low affinity immunoglobulin epsilon Fc receptor membrane-bound form,BLAST-2,CD23A ,Immunoglobulin E-binding factor,C-type lectin domain family 4 member J,Fc-epsilon-RII,F
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

CD23产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CD3-H82Q5
Human
Biotinylated Human CD23 / Fc epsilon RII Protein, His Tag, Avi Tag
CD3-H5249
Human
Human CD23 / Fc epsilon RII Protein, His Tag

CD23 分子别名

FCER2,CD23,CD23A,CLEC4J,FCE2,IGEBF,FcεRII,FcεRⅡ

CD23 分子背景

Cluster of differentiation 23 (CD23) is also known as Low affinity immunoglobulin epsilon Fc receptor (FCER2), C-type lectin domain family 4 member J (CLEC4J), Fc-epsilon-RII (FcεRII), Immunoglobulin E-binding factor (IGEBF), is the "low-affinity" receptor for IgE, an antibody isotype involved in allergy and resistance to parasites, and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells, activated macrophages, eosinophils, follicular dendritic cells, and platelets.There are two forms of CD23: CD23a and CD23b. CD23a is present on follicular B cells, whereas CD23b requires IL-4 to be expressed on T-cells, monocytes, Langerhans cells, eosinophils, and macrophages. CD23 is known to have role of transportation in antibody feedback regulation. Antigen that enters the blood stream is captured by antigen specific IgE antibodies. The IgE immune complexes that are formed bind to CD23 molecules on B cells, and are transported to the B cell follicles of the spleen. The antigen is then transferred from CD23+ B cells to CD11c+ antigen presenting cells. The CD11c+ cells in turn present the antigen to CD4+ T cells, which can lead to an enhanced antibody response. In flow cytometry, CD23 is helpful in the differentiation of chronic lymphocytic leukemia (CD23-positive) from mantle cell leukemia (CD23-negative).

CD23 参考文献

CD23临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Epsi-gam GE-2 临床一期 Tunitas 过敏症 详情
Lumiliximab 临床三期 百健艾迪 慢性淋巴细胞白血病, 过敏性鼻炎, 过敏性哮喘 详情
MEDI-4212 MEDI-4212 临床一期 MedImmune 特应性皮炎, 过敏性鼻炎, 过敏性哮喘 详情

消息提示

请输入您的联系方式,再点击提交!

确定